Strategic Options?

[anonymous]

I was expecting the old exploring strategic options in the earnings release, perhaps management has determined that there are no strategic options? Regardless, this won't go on much longer.

 

[anonymous]

I was expecting the old exploring strategic options in the earnings release, perhaps management has determined that there are no strategic options? Regardless, this won't go on much longer.

There are no options left.

MeTooDopa has hit its peak in the US at 1/15th of its original forecast.

the debt load makes an acquisition impossible for anyone that was interested.

the pipeline has not advanced and there is nothing there to add revenue or to partner.

ex US brought in a whopping $1.9 M which further demonstrates the lack of interest out there.

Swami RC would have been better off keeping manufacturing and become a contract manufacturer than to continue this commercial charade.

 

[anonymous]

I was expecting the old exploring strategic options in the earnings release, perhaps management has determined that there are no strategic options? Regardless, this won't go on much longer.

Aside from fact this is a moronic post Acorda Leadership has limitless strategic options.

Just a few: Establish worldwide sales field team of Inbrija to bring in about $500M in revenue by 2024, unless a Covid delay (agin); second, a strategic reverse split to jack share-price and Wall Street attention that will net maybe 50% value gain; third, establish a stronger relationship with Esteve to improve margins on Inbrija massive sales in Deutschland. Finally, more funding to the WORLDWIDE PR campaign to complement the US PR activity.

These just a few my friend !

 

[anonymous]

Aside from fact this is a moronic post Acorda Leadership has limitless strategic options.

Just a few: Establish worldwide sales field team of Inbrija to bring in about $500M in revenue by 2024, unless a Covid delay (agin); second, a strategic reverse split to jack share-price and Wall Street attention that will net maybe 50% value gain; third, establish a stronger relationship with Esteve to improve margins on Inbrija massive sales in Deutschland. Finally, more funding to the WORLDWIDE PR campaign to complement the US PR activity.

These just a few my friend !

Here we go with the bullsshit forecasts again. U said that 3 years ago for the US AND quoted 700m market. 3 years later your can’t break 10m a quarter in the larger market I. The world. Only strategic options. Is…. Get o. Your knees……. And pray

 

[anonymous]

There are no options left.

MeTooDopa has hit its peak in the US at 1/15th of its original forecast.

the debt load makes an acquisition impossible for anyone that was interested.

the pipeline has not advanced and there is nothing there to add revenue or to partner.

ex US brought in a whopping $1.9 M which further demonstrates the lack of interest out there.

Swami RC would have been better off keeping manufacturing and become a contract manufacturer than to continue this commercial charade.

and the 1.9 m was a channel stocking. U won’t get another order for 12 months.

 

[anonymous]

Aside from fact this is a moronic post Acorda Leadership has limitless strategic options.

Just a few: Establish worldwide sales field team of Inbrija to bring in about $500M in revenue by 2024, unless a Covid delay (agin); second, a strategic reverse split to jack share-price and Wall Street attention that will net maybe 50% value gain; third, establish a stronger relationship with Esteve to improve margins on Inbrija massive sales in Deutschland. Finally, more funding to the WORLDWIDE PR campaign to complement the US PR activity.

These just a few my friend !

Too bad we don't have you at the helm instead of RC, the company would have gone under a long time ago.

 

[anonymous]

Here we go with the bullsshit forecasts again. U said that 3 years ago for the US AND quoted 700m market. 3 years later your can’t break 10m a quarter in the larger market I. The world. Only strategic options. Is…. Get o. Your knees……. And pray

WWw


You are Wrong! We predicted $700million before the Covid ,high interest rates, war in UK Ukraine, intern issues, and employees turnover . PR hindered by negative posts.

 

[anonymous]

Here we go with the bullsshit forecasts again. U said that 3 years ago for the US AND quoted 700m market. 3 years later your can’t break 10m a quarter in the larger market I. The world. Only strategic options. Is…. Get o. Your knees……. And pray

WWw


You are Wrong! We predicted $700million before the Covid ,high interest rates, war in UK Ukraine, intern issues, and employees turnover . PR hindered by negative posts.

 

[anonymous]

Far from dead; you seen what institutions are long on this. Another easy pandemic recovery play.

 

[anonymous]

Far from dead; you seen what institutions are long on this. Another easy pandemic recovery play.

You will burn thru cash before that happens

 

[anonymous]

WWw


You are Wrong! We predicted $700million before the Covid ,high interest rates, war in UK Ukraine, intern issues, and employees turnover . PR hindered by negative posts.

Hey, your CEO voted for this clown car administration. He must have recognized his leadership style and results.

one more failure in long list for Ashram Ronnie

 

[anonymous]

I was expecting the old exploring strategic options in the earnings release, perhaps management has determined that there are no strategic options? Regardless, this won't go on much longer.

Strategic is not a word that should ever be used for Acorda

 

[anonymous]

Strategic is not a word that should ever be used for Acorda

DISAGREE 1000% !!!!
Leadership is 100% STRATEGIC MENSA execution !!!
Lesser minds may NOT understand strategic moves and LONG TERM play to 100% REBOUND glory !!!
Please hold off negativity untill you see the REBOUND !!!

 

[anonymous]

Strategic is not a word that should ever be used for Acorda

other terms not used when discussing ACOR

patent protection
Pipeline
Growth
Leadership
Execution
Pre launch planning
Career
Innovation

 

[anonymous]

other terms not used when discussing ACOR

patent protection
Pipeline
Growth
Leadership
Execution
Pre launch planning
Career
Innovation

Disagree 1000% !
The Leadership follows ALL these "terms" with long term SUCCESS !!
Please do not post NEGATIVE BS !!!!
This site is ........... !!!

 

[anonymous]

Very good chance we can acquire Regeneron- they’ll have major shareholding’s but the need our Dr to step into the CEO chair of the combination Ned companies.

 

[anonymous]

Very good chance we can acquire Regeneron- they’ll have major shareholding’s but the need our Dr to step into the CEO chair of the combination Ned companies.

With your cash burn and lackluster sales you will never get financing to purchase anything…. will be lucky to afford a dumpster that habibs cousin sleeps in outside your tiny downsized office

 

[anonymous]

With your cash burn and lackluster sales you will never get financing to purchase anything…. will be lucky to afford a dumpster that habibs cousin sleeps in outside your tiny downsized office

LOFL !!
The CEO has pipeline to git the financing !
This is probably a 'dunn deal' as the saying goes.
The smaller office facility only temp and will blossom when deal is dunn.
You obviously not an employee an ignorant !!

 

[anonymous]

LOFL !!
The CEO has pipeline to git the financing !
This is probably a 'dunn deal' as the saying goes.
The smaller office facility only temp and will blossom when deal is dunn.
You obviously not an employee an ignorant !!

Your obviously not one with any basic business sense…. Or understanding of the English language.

 

[anonymous]

Very good chance we can acquire Regeneron- they’ll have major shareholding’s but the need our Dr to step into the CEO chair of the combination Ned companies.

Habib,

your wishful thinking aside. Care to explain how some fourth tier Pharma company with a market cap of $10M is going to buy a premier biotech with a market cap of $68B?

You don’t have money for rent, you aren’t buying anything.